Early Phase/Multi Tumor Trials
Below is a list of early phase clinical trials that may recruit from many different cancer diseases. To find out more about a particular clinical trial, click on the “study Information link” for the trial. Once you are in the study specific page, there is a link to contact the study team.
STUDY17022
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF- Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFB. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Study InformationSTUDY17613
Prospective ctDNA Monitoring in Exceptional Responders to Immunotherapy: A Pilot Study
Evaluate the association between ctDNA status (detectable vs non-detectable) at the time of progression and duration of exceptional response (DOER). Evaluate the association between ctDNA levels measured over time and DOER. Evaluate the association between rising vs not rising (stable or non-detectable) ctDNA levels and DOER. Characterize ctDNA levels in patients who resume immunotherapy in setting of progressive disease (PD). Estimate median overall survival (OS).
Study InformationSTUDY23589
A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.
Study InformationSTUDY23849
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD and/or RP2D. Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1311 as monotherapy.
Study InformationSTUDY23966
A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors
To evaluate the safety and tolerability of IMP1734. To determine the MTD (or MAD) and RDE. To characterize the plasma PK profile of single and multiple doses of IMP1734. To assess preliminary anti-tumor activity of IMP1734.
Study InformationSTUDY24162
A phase 1b study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serious ovarian cancer
To compare the safety, tolerability, and preliminary efficacy of sovilnesib at selected dose levels (DLs) to determine the Recommended Phase 2 Dose (RP2D). To further assess the efficacy of sovilnesib. To characterize the pharmacokinetics (PK) of sovilnesib.
Study InformationSTUDY24970
A Phase 1, open-label, dose-escalation and dose-expansion study evaluating AO-252, a protein-protein interaction inhibitor of TACC3, in patients with advanced solid tumors with or without brain metastases
The primary objectives are to determine the MTD/RP2D and safety profile of AO-252 in patients with advanced solid tumors. Secondary objectives:The secondary objectives are to: Determine antitumor activity of AO-252 as assessed by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to progression (TTP), and time to response (TTR)Determine the PK profile of AO-252 including maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and area under the plasma concentration-time curve (AUC) over the dosing interval. Exploratory Objectives: The exploratory objectives are to: Determine antitumor activity of AO-252 as assessed by progression-free survival (PFS) and overall survival (OS). Evaluate the effect of AO-252 on clinically relevant tumor markers (phospho-histone H3, gammaH2AX, cleaved-PARP, TP53, TACC3, and CA levels).
Study InformationSTUDY25269
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.
Study InformationSTUDY26329
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
To evaluate the safety and tolerability of AT03-65 in subjects with advanced/ metastatic solid tumors. To explore the MTD by observing dose limiting toxicity of AT03-65 and/or to provide support for the determination of the RP2D.
Study InformationSTUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.
Study Information